Extracellular vesicles as a novel rescue therapy for fetal lung vasculature in congenital diaphragmatic hernia
About This Grant
Project Summary / Abstract Congenital diaphragmatic hernia (CDH) is a birth defect where the fetal diaphragm does not form properly and organs from the abdomen move into the chest, affecting lung development. As a result, one-third of U.S. infants with CDH dies, mainly due to the abnormal development of lung blood vessels (vascular remodeling) and high blood pressure after birth. Although surgery after birth can fix the defect in the diaphragm, it cannot reverse the damage already done to the lungs before birth. Experts agree that a therapy that promotes lung development and reverses vascular remodeling before birth is urgently needed, but currently no such treatment exists. Our team has established a new therapy for fetal lung regeneration using stem cell-derived nanoparticles, called extracellular vesicles (EVs). These particles contain bioactive molecules (proteins, lipids, and miRNAs) that are key for normal lung development. In experimental studies using models of CDH, we showed that prenatal EV treatment improves all aspects of lung development, including formation of lung vasculature. However, the mechanisms behind EV beneficial effects on fetal lung vessels in CDH remain undefined. The objectives of this proposal are to determine how EV therapy mediates lung vascular regeneration and which CDH babies are most likely to benefit from it. Our central hypothesis is that EVs reverse fetal lung vascular remodeling by delivering miRNAs that are critical for normal vessel development, benefiting those with the most severe disease. We will test our hypothesis with three specific aims: Aim1 will study how EVs promote the regeneration of CDH lung endothelial cells, the most critical component of blood vessels; Aim2 will employ cutting-edge technology (spatial transcriptomics and proteomics) to determine the molecular pathways that are modulated by EV treatment throughout the CDH lung; Aim3 will test the effects of prenatal EV treatment on varying degrees of CDH severity by assessing lung morphology with histology and advanced imaging (micro-CT), and lung function after birth with ventilation and echocardiography studies. This project combines the expertise of specialists in EV biology and regenerative medicine, lung development and CDH modeling, spatial transcriptomics and proteomics, fetal surgery and clinical outcomes. This team will advance the knowledge on CDH lung disease and lay the foundation for the clinical translation of a novel EV- based strategy that will improve survival and quality of life for CDH babies and their families.
Grant Summary
Extracellular vesicles as a novel rescue therapy for fetal lung vasculature in congenital diaphragmatic hernia is a NHLBI - National Heart Lung and Blood Institute grant providing up to $545K for university, nonprofit, healthcare org. Applications are due 2031-03-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $545K
2031-03-31
- 1Confirm your organization is eligible for Extracellular vesicles as a novel rescue therapy for fetal lung vasculature in congenital diaphragmatic hernia from NHLBI - National Heart Lung and Blood Institute, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NHLBI - National Heart Lung and Blood Institute before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NHLBI - National Heart Lung and Blood Institute's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Extracellular vesicles as a novel rescue therapy for fetal lung vasculature in congenital diaphragmatic hernia: Frequently Asked Questions
Who is eligible for the Extracellular vesicles as a novel rescue therapy for fetal lung vasculature in congenital diaphragmatic hernia?
Extracellular vesicles as a novel rescue therapy for fetal lung vasculature in congenital diaphragmatic hernia is offered by NHLBI - National Heart Lung and Blood Institute and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Extracellular vesicles as a novel rescue therapy for fetal lung vasculature in congenital diaphragmatic hernia provide?
Extracellular vesicles as a novel rescue therapy for fetal lung vasculature in congenital diaphragmatic hernia provides up to $545K per award from NHLBI - National Heart Lung and Blood Institute. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Extracellular vesicles as a novel rescue therapy for fetal lung vasculature in congenital diaphragmatic hernia deadline?
Applications for Extracellular vesicles as a novel rescue therapy for fetal lung vasculature in congenital diaphragmatic hernia are due 2031-03-31 (open). Because deadlines can change, verify the date with the funder, NHLBI - National Heart Lung and Blood Institute, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Extracellular vesicles as a novel rescue therapy for fetal lung vasculature in congenital diaphragmatic hernia?
To apply for Extracellular vesicles as a novel rescue therapy for fetal lung vasculature in congenital diaphragmatic hernia, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NHLBI - National Heart Lung and Blood Institute.